NPI 1669534160: Open Payments
NPI 1669534160. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,037 in 43 payments from 9 companies in 2025. Trend: 2023 $806 · 2024 $1,250 · 2025 $1,037
Food & beverage: $862Education: $176
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 15 | $520 |
| GlaxoSmithKline, LLC. | 17 | $264 |
| Optinose US, Inc. | 3 | $90 |
| GENZYME CORPORATION | 2 | $59 |
| Organon LLC | 2 | $26 |
| Novartis Pharmaceuticals Corporation | 1 | $22 |
| AstraZeneca Pharmaceuticals LP | 1 | $20 |
| Blueprint Medicines Corporation | 1 | $19 |
| Amgen Inc. | 1 | $18 |
Products named: DUPIXENT, NUCALA, TRELEGY ELLIPTA, Xhance, AYVAKIT, VTAMA, AIRSUPRA, TEZSPIRE.
